Grail Encouraged By New Circulating Cell-free Genome Atlas Data
Executive Summary
A sub-analysis of the Circulating Cell-free Genome Atlas study show Grail's genome-sequencing technology may be able to detect early-stage lung cancer through DNA signals in the blood.
You may also be interested in...
Grail’s Liquid Biopsy Can Detect Numerous Deadly Cancer Types Early
Grail announced results from an initial validation study that showed its early-detection blood test could identify 12 of the deadliest cancers with a low rate of false-positive results.
VC Deals Analysis: Asia Investors Pour Money Into Grail And May's Other Big Deals
Asian investors' unrelenting pursuit of medtech ventures continued to crescendo in May. The participants in the largest round so far this year, the $300m series C by Illumina spin-out Grail, are all China-based funds.
Market Intel: Liquid Biopsies For Cancer Screening – Far From Reach Or Close At Hand?
While liquid biopsy is becoming routine for cancer treatment stratification and monitoring, using blood tests to screen for early cancer in asymptomatic people remains a tantalizing target. Some question how practical such a test could be but several companies are already en route - some further down the road than others - to achieve this goal. Illumina spin-out Grail is one of these companies and while it is not alone, in a field where size matters, it may have an advantage. This article delves deeper into how these different technologies work and when they could reach the market.